Tenax Therapeutics, Inc. (TENX)
NASDAQ: TENX · Real-Time Price · USD
12.89
-0.04 (-0.31%)
At close: Jun 25, 2026, 4:00 PM EDT
12.89
0.00 (0.00%)
After-hours: Jun 25, 2026, 4:04 PM EDT
Tenax Therapeutics Employees
As of December 31, 2025, Tenax Therapeutics had 16 total employees, including 14 full-time and 2 part-time employees. The number of employees increased by 10 or 166.67% compared to the previous year.
Employees
16
Change (1Y)
10
Growth (1Y)
166.67%
Revenue / Employee
n/a
Profits / Employee
-$3,619,188
Market Cap
657.04M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 16 | 10 | 166.67% | 14 | 2 |
| Dec 31, 2024 | 6 | 0 | - | 4 | 2 |
| Dec 31, 2023 | 6 | -2 | -25.00% | 5 | 1 |
| Dec 31, 2022 | 8 | -1 | -11.11% | 7 | 1 |
| Dec 31, 2021 | 9 | -1 | -10.00% | 8 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| CorMedix | 191 |
| Rigel Pharmaceuticals | 174 |
| Aclaris Therapeutics | 73 |
| CytomX Therapeutics | 69 |
| Oculis Holding AG | 60 |
| Candel Therapeutics | 55 |
| Climb Bio | 29 |
| Faeth Therapeutics | 29 |
TENX News
- 3 days ago - Tenax Therapeutics price target raised to $40 from $34 at Guggenheim - TheFly
- 3 days ago - Tenax Therapeutics initiated with a Buy at Chardan - TheFly
- 13 days ago - Tenax Therapeutics price target raised to $50 from $20 at Piper Sandler - TheFly
- 6 weeks ago - Tenax Therapeutics reports Q1 EPS (35c), consensus (40c) - TheFly
- 6 weeks ago - Tenax Therapeutics Earnings release: Q1 2026 - Filings
- 6 weeks ago - Tenax Therapeutics Quarterly report: Q1 2026 - Filings
- 6 weeks ago - Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire